Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Renzapride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 5/20 | 0.78 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 3/20 | 0.78 |
| ▸ | HTR3B known ✓ | O95264 | 3/20 | 0.78 |
| ▸ | HTR3D known ✓ | Q70Z44 | 3/20 | 0.78 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 3/20 | 0.78 |
| ▸ | HTR4 known ✓ | Q13639 | 2/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.78 |
| ▸ | DRD3 | P35462 | 4/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.65 |
| ▸ | DRD2 | P14416 | 3/20 | 0.65 |
| ▸ | DRD4 | P21917 | 3/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.65 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | MPO | P05164 | 1/20 | 0.65 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.65 |
| ▸ | HTR2A | P28223 | 1/20 | 0.65 |
| ▸ | HTR2C | P28335 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Renzapride SCHEMBL4534994 | 0.88 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL17037 | 0.88 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL678616 | 0.88 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL5371909 | 0.87 | HTR3A (0.98) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL5367707 | 0.87 | HTR3A (0.98) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL5765864 | 0.87 | HTR3A (0.98) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL1650356 | 0.86 | HTR3A (0.96) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL5767174 | 0.86 | HTR3A (0.96) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL5371617 | 0.86 | HTR3A (0.96) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Metoclopramide SCHEMBL18629 | 0.81 | HTR4 (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3956025-A1 | CGRP ANTAGONISTS FOR THE TREATMENT OF MEDICATION OVERUSE HEADACHE, POST-TRAUMATIC HEADACHE, POST-CONCUSSION SYNDROME AND VERTIGO | Allergan Sales, LLC (US) | 2022-02-23 | — | — | EP | claimed |
| EP-3817766-A2 | COMBINATION THERAPY WITH CGRP ANTAGONISTS AND CLOSTRIDIAL DERIVATIVES | Allergan Pharmaceuticals International Limited (IE) | 2021-05-12 | — | — | EP | claimed |
| US-20200383983-A1 | CGRP ANTAGONISTS FOR THE TREATMENT OF MEDICATION OVERUSE HEADACHE, POST-TRAUMATIC HEADACHE, POST-CONCUSSION SYNDROME AND VERTIGO | ALLERGAN SALES, LLC | 2020-12-10 | — | — | US | claimed |
| WO-2020214906-A1 | CGRP ANTAGONISTS FOR THE TREATMENT OF MEDICATION OVERUSE HEADACHE, POST-TRAUMATIC HEADACHE, POST-CONCUSSION SYNDROME AND VERTIGO | ALLERGAN SALES, LLC (US) | 2020-10-22 | — | — | WO | claimed |
| WO-2020008402-A2 | COMBINATION THERAPY WITH CGRP ANTAGONISTS AND CLOSTRIDIAL DERIVATIVES | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2020-01-09 | — | — | WO | claimed |
| US-20130231311-A1 | NOVEL FORMULATIONS FOR TREATMENT OF MIGRAINE | ZOGENIX, INC. | 2013-09-05 | — | — | US | claimed |
| US-20110118189-A1 | NOVEL FORMULATIONS FOR TREATMENT OF MIGRAINE | ZOGENIX, INC. | 2011-05-19 | — | — | US | claimed |
| EP-2273880-A1 | NOVEL FORMULATIONS FOR TREATMENT OF MIGRAINE | Zogenix, Inc. (US) | 2011-01-19 | — | — | EP | claimed |
| WO-2009134336-A1 | NOVEL FORMULATIONS FOR TREATMENT OF MIGRAINE | ZOGENIX, INC. (US) | 2009-11-05 | — | — | WO | claimed |
| US-20240066028-A1 | COMPOSITIONS FOR IMPROVED DELIVERY OF CGRP INHIBITORS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2024-02-29 | — | — | US | disclosed |
| EP-4302828-A2 | COMBINATION THERAPY WITH CGRP ANTAGONISTS AND CLOSTRIDIAL DERIVATIVES | Allergan Pharmaceuticals International Limited (IE) | 2024-01-10 | — | — | EP | disclosed |
| EP-4284505-A1 | PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS AND METHODS OF THEIR USE | Pfizer Ireland Pharmaceuticals (IE) | 2023-12-06 | — | — | EP | disclosed |
| EP-4263571-A1 | COMPOSITIONS FOR IMPROVED DELIVERY OF CGRP INHIBITORS | Pfizer Ireland Pharmaceuticals (IE) | 2023-10-25 | — | — | EP | disclosed |
| EP-4247364-A1 | COMPOSITIONS FOR IMPROVED DELIVERY OF CGRP INHIBITORS | Pfizer Ireland Pharmaceuticals (IE) | 2023-09-27 | — | — | EP | disclosed |
| EP-2756756-A1 | Novel formulations for treatment of migraine | Zogenix, Inc. (US) | 2014-07-23 | — | — | EP | disclosed |
| US-20140148485-A1 | NOVEL FORMULATIONS FOR TREATMENT OF MIGRANE | ZOGENIX, INC. | 2014-05-29 | — | — | US | disclosed |
| US-20130231311-A1 | NOVEL FORMULATIONS FOR TREATMENT OF MIGRAINE | ZOGENIX, INC. | 2013-09-05 | — | — | US | disclosed |
| US-20110118189-A1 | NOVEL FORMULATIONS FOR TREATMENT OF MIGRAINE | ZOGENIX, INC. | 2011-05-19 | — | — | US | disclosed |
| EP-2273880-A1 | NOVEL FORMULATIONS FOR TREATMENT OF MIGRAINE | Zogenix, Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009134336-A1 | NOVEL FORMULATIONS FOR TREATMENT OF MIGRAINE | ZOGENIX, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066028-A1 | COMPOSITIONS FOR IMPROVED DELIVERY OF CGRP INHIBITORS | CALCB, CALCA, CALCRL | HTR3A 766/4885HTR3E 871/4885HTR3B 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.